A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors
{{output}}
Purpose Brentuximab vedotin (BV) is an anti-CD30 antibody-drug conjugate used in the treatment of several types of lymphomas. Expression of the target antigen has also been reported on a variety of malignant tumors of nonlymphoid origin. This phase 2, open-lab... ...
